IMUX
What one share of Immunic holds
Pharmaceutical Preparations
Immunic, Inc. (“Immunic," “we,” “us,” “our” or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany.
Immunic’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.00 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.16 |
| Dividends | $0.00 |
| Cash and investments | $11.37 |
| Book value | $9.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$1,770 | $43.88 | −$1,315 | — | $2,034 |
| 2015 | — | −$1,034 | $46.52 | −$1,039 | — | $1,351 |
| 2016 | — | −$652.63 | $8.86 | −$578.73 | — | $909.14 |
| 2017 | — | −$653.28 | $8.59 | −$515.34 | — | −$157.39 |
| 2018 | — | −$136.28 | $0.38 | −$115.35 | $0.00 | −$303.92 |
| 2019 | — | −$45.24 | $0.07 | −$37.04 | $0.00 | $54.32 |
| 2020 | — | −$28.10 | $0.09 | −$29.54 | $0.00 | $75.01 |
| 2021 | — | −$39.30 | $0.03 | −$35.22 | $0.00 | $48.27 |
| 2022 | — | −$37.84 | $0.04 | −$20.51 | $0.00 | $28.92 |
| 2023 | — | −$21.12 | $0.08 | −$16.06 | $0.00 | $6.40 |
| 2024 | — | −$10.03 | $0.03 | −$8.49 | $0.00 | $2.04 |
| 2025 | — | −$6.24 | $0.01 | −$5.52 | $0.00 | −$0.55 |